Jim Simons
LRMR icon

Jim Simons’s Larimar Therapeutics LRMR Stock Holding History

Jim Simons’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.33M Buy
739,942
+442,676
+149% +$1.77M 0.01% 1607
2025
Q4 		$1.13M Sell
297,266
-561,376
-65% -$2.18M ﹤0.01% 2207
2025
Q3 		$2.77M Buy
858,642
+296,900
+53% +$1.11M ﹤0.01% 1859
2025
Q2 		$1.62M Sell
561,742
-413,229
-42% -$957K ﹤0.01% 2245
2025
Q1 		$2.1M Buy
974,971
+461,429
+90% +$1.46M ﹤0.01% 1961
2024
Q4 		$1.99M Buy
513,542
+159,700
+45% +$1.05M ﹤0.01% 2056
2024
Q3 		$2.32M Buy
353,842
+75,500
+27% +$607K ﹤0.01% 1923
2024
Q2 		$2.02M Sell
278,342
-225,100
-45% -$1.72M ﹤0.01% 1882
2024
Q1 		$3.82M Buy
503,442
+256,400
+104% +$2M 0.01% 1586
2023
Q4 		$1.12M Buy
247,042
+1,700
+0.7% +$5.74K ﹤0.01% 2330
2023
Q3 		$969K Sell
245,342
-36,232
-13% -$137K ﹤0.01% 2324
2023
Q2 		$881K Buy
281,574
+98,832
+54% +$403K ﹤0.01% 2549
2023
Q1 		$828K Sell
182,742
-46,032
-20% -$241K ﹤0.01% 2597
2022
Q4 		$945K Sell
228,774
-67,593
-23% -$231K ﹤0.01% 2568
2022
Q3 		$948K Buy
296,367
+120,825
+69% +$303K ﹤0.01% 2532
2022
Q2 		$344K Buy
175,542
+2,800
+2% +$8.27K ﹤0.01% 3372
2022
Q1 		$700K Sell
172,742
-20,032
-10% -$131K ﹤0.01% 2970
2021
Q4 		$2.08M Sell
192,774
-53,500
-22% -$595K ﹤0.01% 2114
2021
Q3 		$2.84M Buy
246,274
+50,500
+26% +$606K ﹤0.01% 1830
2021
Q2 		$1.92M Sell
195,774
-16,700
-8% -$189K ﹤0.01% 2286
2021
Q1 		$3.1M Sell
212,474
-8,900
-4% -$162K ﹤0.01% 1944
2020
Q4 		$4.74M Buy
221,374
+22,300
+11% +$447K 0.01% 1626
2020
Q3 		$3.02M Sell
199,074
-9,500
-5% -$120K ﹤0.01% 1871
2020
Q2 		$2.68M Buy
208,574
+28,528
+16% +$332K ﹤0.01% 2005
2020
Q1 		$1.66M Sell
180,046
-18,760
-9% -$247K ﹤0.01% 2145
2019
Q4 		$2.65M Buy
198,806
+16,254
+9% +$155K ﹤0.01% 2186
2019
Q3 		$1.62M Buy
182,552
+42,694
+31% +$468K ﹤0.01% 2386
2019
Q2 		$2M Buy
139,858
+58,143
+71% +$1.55M ﹤0.01% 2331
2019
Q1 		$2.69M Buy
81,715
+16,998
+26% +$871K ﹤0.01% 2161
2018
Q4 		$3.84M Buy
64,717
+525
+0.8% +$51.8K ﹤0.01% 1884
2018
Q3 		$9.01M Buy
64,192
+10,050
+19% +$1.22M 0.01% 1426
2018
Q2 		$6.65M Buy
54,142
+6,809
+14% +$578K 0.01% 1598
2018
Q1 		$4.23M Sell
47,333
-8,581
-15% -$727K ﹤0.01% 1917
2017
Q4 		$3.1M Sell
55,914
-2,644
-5% -$119K ﹤0.01% 2094
2017
Q3 		$2.47M Buy
58,558
+21,300
+57% +$886K ﹤0.01% 2189
2017
Q2 		$1.57M Buy
37,258
+22,241
+148% +$1.14M ﹤0.01% 2390
2017
Q1 		$840K Buy
+15,017
New +$746K ﹤0.01% 2605
2015
Q3 		– Sell
-2,183
Closed -$907K – 3274
2015
Q2 		$907K Sell
2,183
-4,348
-67% -$1.82M ﹤0.01% 2496
2015
Q1 		$3.1M Buy
+6,531
New +$3.1M 0.01% 1670

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Jim Simons's LRMR Position: Q1 2026 in Review

Jim Simons increased its Larimar Therapeutics (LRMR) stake by 149% in Q1 2026, buying an estimated $1.77M and bringing the position to 739,942 shares worth $3.33M. The position accounts for 0.01% of the portfolio, ranked #1607.

Jim Simons first reported a position in LRMR in Q1 2015 and has held it in 39 quarters since. The position peaked at $9.01M in Q3 2018. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Jim Simons held 739,942 shares of Larimar Therapeutics worth $3.33M as of Q1 2026.
  • Jim Simons bought 442,676 Larimar Therapeutics shares in Q1 2026, an estimated $1.77M.
  • Larimar Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1607 holding.
  • Jim Simons first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 39 quarters since.
  • Jim Simons's Larimar Therapeutics position peaked at $9.01M in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.